Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

316
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
316
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

348
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
348

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Efficacy of PAUL Glaucoma Implant® for Refractory Uveitic Glaucoma.

Ocular immunology and inflammation·2026
Same author

Performance of the ISOLD Score (Interleukin Score for IntraOcular Lymphoma Diagnosis) in the Diagnosis of Vitreoretinal Lymphoma in Clinical Practice.

American journal of ophthalmology·2026
Same author

Toxoplasmosis meets the World Health Organization criteria for a neglected tropical disease.

PLoS neglected tropical diseases·2026
Same author

Bilateral Giant Pigment Epithelial Detachments and Unilateral RPE Tear and Exudative Retinal Detachment After Tadalafil Exposure: Case Report and Review of the Literature.

Retinal cases & brief reports·2026
Same author

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Neurology·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026

Related Experiment Video

Updated: Mar 25, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.3K

Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?

Léa Jouve1, Rabah Benrabah2, Emmanuel Héron2

  • 1a Ophthalmology Department , Centre Hospitalier National des Quinze-Vingt , Paris , France.

Ocular Immunology and Inflammation
|February 24, 2016
PubMed
Summary

Multiple sclerosis (MS)-related uveitis often has a favorable outcome. However, interferon-beta treatment is linked to more severe and chronic uveitis, suggesting it should not be used solely for ocular inflammation.

Keywords:
Corticosteroidscystoid macular edemaimmunosuppressive drugsinterferon-betarelapsing-remitting MSuveitis

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 25, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.3K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Area of Science:

  • Ophthalmology
  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS)-related uveitis lacks extensive data on optimal management.
  • Understanding the clinical course and treatment impact is crucial for patient care.

Purpose of the Study:

  • To characterize clinical features of MS-associated uveitis.
  • To evaluate the effect of MS treatments on uveitis progression.

Main Methods:

  • Retrospective, multicenter study design.
  • Patients classified into two groups: without (group 1) and with (group 2) immunomodulatory drugs.
  • Review of uveitis characteristics and treatment regimens.

Main Results:

  • 68 eyes from 36 patients analyzed; 17 in group 1, 19 in group 2.
  • Uveitis preceded neurological symptoms in 78% of cases.
  • Group 2 (on immunomodulatory drugs) exhibited more severe uveitis (p<0.05) and a trend towards chronicity (p=0.06).

Conclusions:

  • MS-related uveitis generally shows a favorable course.
  • Interferon-beta therapy is associated with increased uveitis severity and chronicity.
  • Immunosuppressive agents are preferred over interferon-beta for steroid-sparing treatment of intraocular inflammation in MS.